Clareo Health | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Diagnosed with one of the following at least 3 months prior to screening: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder
Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior to screening
You may not be if
Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prominent than TD
Diagnosis of moderate or severe substance use disorder in the last 6 months
History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment
